Soleno Therapeutics Analyst Ratings
Soleno Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Soleno Therapeutics (SLNO) rating was a with a price target of $0.00 to $40.00. The current price Soleno Therapeutics (SLNO) is trading at is $25.59, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/21/2023 | 56.31% | Guggenheim | → $40 | Assumes | → Buy |
| 09/26/2023 | 36.77% | Cantor Fitzgerald | $19 → $35 | Maintains | Overweight |
| 09/15/2023 | -45.29% | Oppenheimer | $8 → $14 | Maintains | Outperform |
| 08/31/2023 | -25.75% | Cantor Fitzgerald | → $19 | Reiterates | Overweight → Overweight |
| 07/11/2023 | -25.75% | Cantor Fitzgerald | → $19 | Initiates Coverage On | → Overweight |
| 05/25/2023 | -68.74% | Oppenheimer | → $8 | Reiterates | → Outperform |
| 03/24/2023 | -68.74% | Oppenheimer | → $8 | Reiterates | → Outperform |
| 09/29/2020 | -68.74% | Guggenheim | → $8 | Initiates Coverage On | → Buy |
| 01/10/2020 | -68.74% | Craig-Hallum | → $8 | Initiates Coverage On | → Buy |
| 12/23/2019 | — | Laidlaw & Co. | Initiates Coverage On | → Buy | |
| 12/23/2019 | -60.92% | Oppenheimer | → $10 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/21/2023 | 56.31% | 古根海姆 | → 40 美元 | 假設 | → 購買 |
| 09/26/2023 | 36.77% | 坎託·菲茨傑拉德 | 19 美元 → 35 美元 | 維護 | 超重 |
| 09/15/2023 | -45.29% | 奧本海默 | 8 美元 → 14 美元 | 維護 | 跑贏大盤 |
| 08/31/2023 | -25.75% | 坎託·菲茨傑拉德 | → 19 美元 | 重申 | 超重 → 超重 |
| 07/11/2023 | -25.75% | 坎託·菲茨傑拉德 | → 19 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 05/25/2023 | -68.74% | 奧本海默 | → 8 美元 | 重申 | → 跑贏大盤 |
| 2023 年 3 月 24 日 | -68.74% | 奧本海默 | → 8 美元 | 重申 | → 跑贏大盤 |
| 09/29/2020 | -68.74% | 古根海姆 | → 8 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 10 月 1 日 | -68.74% | Craig-Hallum | → 8 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 12/23/2019 | — | Laidlaw & Co. | 啓動覆蓋範圍開啓 | → 購買 | |
| 12/23/2019 | -60.92% | 奧本海默 | → 10 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Soleno Therapeutics (SLNO)?
Soleno Therapeutics（SLNO）的目標價格是多少？
The latest price target for Soleno Therapeutics (NASDAQ: SLNO) was reported by Guggenheim on November 21, 2023. The analyst firm set a price target for $40.00 expecting SLNO to rise to within 12 months (a possible 56.31% upside). 7 analyst firms have reported ratings in the last year.
古根海姆於2023年11月21日公佈了索理諾療法（納斯達克股票代碼：SLNO）的最新目標股價。該分析公司將目標股價定爲40.00美元，預計SLNO將在12個月內升至12個月內（可能上漲56.31％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Soleno Therapeutics (SLNO)?
Soleno Therapeutics（SLNO）的最新分析師評級是多少？
The latest analyst rating for Soleno Therapeutics (NASDAQ: SLNO) was provided by Guggenheim, and Soleno Therapeutics their buy rating.
古根海姆對索理諾療法（納斯達克股票代碼：SLNO）的最新分析師評級由古根海姆提供，索理諾療法提供了買入評級。
When is the next analyst rating going to be posted or updated for Soleno Therapeutics (SLNO)?
Soleno Therapeutics（SLNO）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Soleno Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Soleno Therapeutics was filed on November 21, 2023 so you should expect the next rating to be made available sometime around November 21, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與索理諾療法的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Soleno Therapeutics的最新評級是在2023年11月21日公佈的，因此您應該預計下一個評級將在2024年11月21日左右公佈。
Is the Analyst Rating Soleno Therapeutics (SLNO) correct?
分析師對Soleno Therapeutics（SLNO）的評級是否正確？
While ratings are subjective and will change, the latest Soleno Therapeutics (SLNO) rating was a with a price target of $0.00 to $40.00. The current price Soleno Therapeutics (SLNO) is trading at is $25.59, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但索理諾療法（SLNO）的最新評級爲A，目標股價爲0.00美元至40.00美元。索理諾療法（SLNO）目前的交易價格爲25.59美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。
